Empagliflozin

Green-G

Brand Name(s):Jardiance

Indication:Diabetes mellitus – Type 2

Rationale:

Considered:Jul-14

Review Date:Feb-24

Comments:
Drug Safety Update
SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum)
Feb 2019
…………………………
NICE NG28 Update Type 2 diabetes in adults: management
May 2017
…………………………
NICE TA390
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
May 2016
…………………………
Update
Risk of diabetic ketoacidosis
April 2016
…………………………
NICE guidelines (NG28)
Diabetes in adults:management
Document available at:https://www.nice.org.uk/guidance/ng28/resources/type-2-diabetes-in-adults-management-1837338615493
Dec 2015
…………………………
NICE guidelines [NG18]
Diabetes (type 1 and type 2) in children and young people: diagnosis and management
Full document available at:http://www.nice.org.uk/guidance/ng18
Aug 2015
…………………………
NICE TA 336
Empagliflozin in combination therapy for treating type 2 diabetes
Full details available at:http://www.nice.org.uk/guidance/ta336/resources/guidance-empagliflozin-in-combination-therapy-for-treating-type2diabetes-pdf

March 2015
…………………………
Drug Safety Update
MHRA advises clinicians to test for raised ketones in patients on SGLT2 inhibitors.
Full guidance available at:https://www.gov.uk/drug-safety-update/sglt2-inhibitors-canagliflozin-dapagliflozin-empagliflozin-risk-of-diabetic-ketoacidosis
June 2015